Corbus Pharmaceuticals Holdings (CRBP) Cash from Financing Activities (2013 - 2025)

Corbus Pharmaceuticals Holdings' Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $2.9 million for Q3 2025.

• On a quarterly basis, Cash from Financing Activities fell 88.62% year-over-year to $2.9 million in Q3 2025; TTM through Sep 2025 was $2.8 million, a 98.28% decrease from a year earlier, with the FY2024 full-year figure at $166.6 million, up 6004.93% from the prior year.
• Cash from Financing Activities rose to $2.9 million in Q3 2025 per CRBP's latest filing, from -$13000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $106.6 million in Q1 2024 and bottomed at -$1.9 million in Q4 2023.
• The 5-year median for Cash from Financing Activities is -$13000.0 (2024), against an average of $13.3 million.
• Across the five-year window, Cash from Financing Activities slumped 912.98% in 2023 and soared 194042.14% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $767938.0 in 2021, then plunged by 69.49% to $234322.0 in 2022, then slumped by 912.98% to -$1.9 million in 2023, then soared by 99.32% to -$13000.0 in 2024, then surged by 22030.77% to $2.9 million in 2025.
• Per Business Quant, the three latest CRBP Cash from Financing Activities figures stand at $2.9 million (Q3 2025), -$13000.0 (Q4 2024), and $25.0 million (Q3 2024).